| CAIBX | CIREX | CAIBX / CIREX | |
| Total Expense Ratio | 0.58 | 0.84 | 69% |
| Annual Report Gross Expense Ratio | 0.58 | 0.84 | 69% |
| Fund Existence | 39 years | 24 years | - |
| Gain YTD | 9.548 | 9.382 | 102% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 250 | 250 | 100% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 128B | 128B | 100% |
| Annual Yield % from dividends | 2.75 | 2.49 | 110% |
| Returns for 1 year | 10.30 | 10.00 | 103% |
| Returns for 3 years | 39.42 | 38.31 | 103% |
| Returns for 5 years | 39.72 | 41.46 | 96% |
| Returns for 10 years | 67.11 | 89.81 | 75% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBDIX | 195.52 | N/A | N/A |
| Franklin Biotechnology Discovery A | |||
| DEVCX | 51.41 | N/A | N/A |
| Nomura Small Cap Value C | |||
| MEFIX | 20.01 | N/A | N/A |
| ClearBridge Emerging Markets FI | |||
| GBLFX | 42.26 | -0.01 | -0.02% |
| American Funds Global Balanced F-2 | |||
| FEXRX | 15.21 | -0.06 | -0.39% |
| First Eagle U.S. SMID Cap Opportunity R6 | |||